The Singapore Health Sciences Authority has approved the new drug application for equecabtagene autoleucel (FUCASO) for adult patients with relapsed or refractory multiple myeloma. The indication applies to patients who progressed on their last therapy and received at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent, and have demonstrated disease progression.
According to a press release by the manufacturer of the drug, IASO Bio, the company plans to supply the therapy globally from its manufacturing infrastructure in China using an international cold-chain logistics network.
Eque-cel, an anti-BCMA CAR-T, has been approved in China for treating patients with relapsed or refractory myeloma who have progressed after at least three prior lines of treatment.
Leave feedback about this